A b s t r a c t
The term triple-negative breast cancer (TNBC) describes tumors that lack expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC has a poor prognosis because of its aggressive tumor biology and because there are currently no targeted agents (such as trastuzumab or tamoxifen) that are effective in treating TNBC. 1, 2 TNBC is characterized by a higher frequency of distant recurrence and death within 3 years after diagnosis compared with patients diagnosed with other subtypes of breast cancer. 3, 4 The prognosis of patients with breast cancer may be influenced by traditional pathologic parameters, such as histologic type, lymphovascular invasion, and TNM stage. However, patients with TNBC with similarities of these parameters may have completely different prognoses. Therefore, it is necessary to identify prognostic biomarkers for patients with TNBC for use in daily clinical practice. Several prognostic factors are proposed as predictors of clinical outcome in patients with TNBC, and some factors, such as CK5/6, EGFR, and Ki-67, have been suggested as candidates. 5 However, their predictive value in patients with TNBC has not been determined.
Lewis X (Le X ), sialyl-Le X , and sialyl-Lewis a are tumorassociated carbohydrate antigens involved in the process of metastasis. 6 Le X was reported to be an important prognostic marker in pheochromocytoma, 7 medullary thyroid carcinoma, 8, 9 papillary thyroid carcinoma, 10 lung cancer, 11 bladder cancer, 12, 13 and medulloblastoma. 14 The expression of Le X in certain breast cancer cell lines has been reported, 15, 16 and shown to be particularly upregulated in tumor tissues and associated with poor prognosis of patients with breast cancer. 17 Furthermore, targeted therapies against the Le X antigen Upon completion of this activity you will be able to:
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have been developed and their effects are being investigated in patients with breast cancer. 18 Despite the implications of cancer heterogeneity leading to different clinical outcomes and different therapeutic options associated with each molecular subtype of breast cancer, and in particular the poor prognosis of patients with TNBC, there are currently no studies assessing Le X expression in TNBC. Therefore, the aim of our study was to determine the prognostic effect of the Le X antigen in patients with TNBC.
Materials and Methods

Patient Selection and Treatment
From July 2001, to September 2005, 158 randomly selected patients who were diagnosed with primary breast cancer with cytology or core needle biopsy and underwent surgical resection at Asan Medical Center, Seoul, Korea, were enrolled in the study. All of the patients had TNBC, defined as a total lack of ER, PR, and HER2 expression. Clinical data, including age, tumor size, nodal status at initial diagnosis, and survival data, were obtained from medical records.
Histologic and Immunohistochemical Evaluation
All histologic data were reviewed by 2 pathologists (Y.W.K. and G.G.). The World Health Organization classification was used for histologic subtyping, and histologic grade was assessed using the modified Bloom-Richardson classification.
Formalin-fixed, paraffin-embedded tissue sections were evaluated using an automatic immunohistochemical staining device (Benchmark XT; Ventana Medical Systems, Tucson, AZ). Briefly, 4-µm-thick whole tissue sections were transferred to poly-L-lysine-coated adhesive slides and dried for 30 minutes at 74°C. After standard heat epitope retrieval in ethylene diaminetetraacetic acid (pH.8.0) for 1 hour, samples were incubated with antibodies to ER (clone 6F11, 1:50 dilution; Novocastra Laboratories, Newcastle, England), PR (1:200 dilution; Dako, Glostrup, Denmark), HER2 (1:500 dilution; Dako), cytokeratin (CK) 5/6 (clone D5/16B4, 1:200 dilution; Zymed, San Francisco, CA), epidermal growth factor receptor (EGFR) (clone 31G7, 1:100 dilution; Zymed), Ki-67 (clone sp6, 1:50 dilution; Thermo Scientific, Tewksbury, MA), and Le X (1:100 dilution; Cell Marque, Rocklin, CA), using an autostainer. Sections were subsequently incubated with the appropriate reagent from the UltraView Universal DAB kit (Ventana Medical Systems) and counterstained with Harris hematoxylin.
ER and PR levels were semiquantitatively evaluated. The estimated proportion of positively stained tumor cells was scored as 0 (none), 1 (< 1/10), 2 (1/10 to 1/3), 3 (1/3 to 2/3), and 4 (> 2/3). The average staining intensity of tumor cells was scored as 0 (none), 1 (weak), 2 (moderate), and 3 (strong). The proportion and intensity scores were added and a total score of 3 or more was considered positive. The HercepTest scoring method was used to determine HER2 status, with HER2-overexpressing tumors being defined as those with scores of 3+ or 2+ after fluorescence in situ hybridization amplification. 19 A sample was considered Le X -positive if more than 5% of definitive cancer cells showed immunohistochemical reactivity against Le X antibodies, as described in a previously published study 20 positive expression of either EGFR or CK5/6 were referred to as basal and cases were considered to have high Ki-67 expression if at least 10% of definitive cancer cells showed immunohistochemical reactivity against Ki-67 antibody as described in previous studies. 5, 21 
Statistical Analyses
Categorical variables were compared using c 2 tests (2-sided Pearson, Fisher exact test, or linear-by-linear association). Overall survival (OS) was defined as the time between the first day of surgery and the date of death (from any cause); patients still alive were censored at the last date of follow-up. Recurrence-free survival (RFS) was defined as the interval between the first day of surgery and the date of disease relapse or death from related causes; patients still alive were censored at the last date of follow-up. OS and RFS rates were estimated using the Kaplan-Meier method and compared using the logrank test. Uni-and multivariate prognostic analyses for OS and RFS were performed using the Cox proportional hazards regression model. The enter method was used to determine a final Cox model. All variables with a P value less than .05 in the univariate analysis were included in our multivariate analysis. All statistical analyses were performed using the statistical software program SPSS, version 18.0 (SPSS, Chicago, IL). Results were considered statistically significant when the P value was less than .05.
Results
Patient Characteristics
Patient characteristics are summarized in ❚Table 1❚. The median follow-up after surgery was 72 months (range, 2.6-112.1 months) in surviving patients. Twenty-five patients experienced relapse or death. The median RFS and OS values were not reached. The 5-year RFS and OS rates were 85.1% and 87.2%, respectively.
Correlation of Le X With Clinicopathologic Variables
The correlations between Le X expression and clinicopathologic variables were investigated using the c 2 test. A total of 23 patients (14.5%) were Le X -positive and 135 patients (85.5%) were Le X -negative ❚Table 2❚. Le X -positive patients were more likely to present with advanced pathologic nodal stage (P = .015). No significant differences were found between the groups with regard to age (P = .11), pT stage (P = .933), histologic type (P = .71), histologic grade (P = .6), lymphovascular invasion (P = .808), basal type (P = .073), Ki-67 labeling index (P = .268), operation type (P = .118), adjuvant chemotherapy regimen (P = .724), and adjuvant radiotherapy (P = .657).
Prognostic Significance of the Le X Antigen
The RFS rate was lower in Le X -positive than in Le X -negative patients (5-year RFS, 61.8% vs 87.5%; P = .002) ❚Figure 1A❚. OS rate was lower in Le X -positive than in Le X -negative patients (5-year OS, 66.7% vs 87.6%; P = .016) ❚Figure 1B❚.
Univariate analyses showed that RFS and OS were significantly associated with lymphovascular invasion and pN stage, whereas pT stage and age were associated with RFS and OS alone, respectively ❚Table 3❚. Multivariate analyses using age, lymphovascular invasion, pT stage, and pN stage as variables showed that Le X expression was a significant independent prognostic factor for RFS (hazard ratio [HR], 2.736; 95% confidence interval [CI], 1.063-7.044; P = .037; Table 3) and OS (HR, 3.281; 95% CI, 1.171-9.190; P = .024; Table 3 ). As expected, TNM stage was an important prognostic factor ❚Figure 2A❚ and ❚Figure 2B❚. Patients with stage III disease showed poorer RFS and OS than those with stage I or II disease (P = .016, Figure 2A ; and P = .018, Figure 2B ). To determine whether Le X expression has additional prognostic value, we performed subgroup analyses according to pathologic stage. Because stage I and II patients showed similar OS, these 2 groups were analyzed together. In the stage I and II subgroups, Le X -positive patients had lower RFS rates (5-year RFS, 76% vs 89.2%) ❚Figure 3A❚ and a lower OS rate (5-year OS, 81.8% vs 89.3%) ❚Figure 3B❚ than Le X -negative patients. In the stage III subgroup, Le X -positive patients had lower RFS (5-year RFS, 33.3% vs 76%; Figure 3A ) and lower OS rates (5-year OS, 42.9% vs 76.5%; Figure 3B ) than Le X -negative patients.
Because age was a significant prognostic factor for OS on univariate analysis, we performed subgroup analyses according to age to determine whether Le X expression is associated with patient age. In the younger subgroup (age < 50 years), Le X -positive patients had a lower RFS (5-year RFS, 37.5% vs 83.7%; P < .001) ❚Figure 4A❚ and a lower OS rate (5-year OS, 37.5% vs 84%; P < .001) ❚Figure 4B❚ than Le X -negative patients. In the older subgroup (age ≥ 50 years), Le X positivity was not significantly associated with either RFS (5-year RFS, 83.1% vs 93.8%; P = .194) ❚Figure 4C❚ or OS (5-year OS, 90% vs 93.7%; P = .661) ❚Figure 4D❚.
Discussion
The findings of our study are important for 2 reasons. Firstly, to our knowledge, this is the first study to evaluate Le X expression as a prognostic factor for survival in patients with TNBC. Secondly, Le X expression allowed further risk stratification in patients who were considered to be at risk on the basis of pathologic stage.
A previous study also reported that Le X expression was associated with poor prognosis in patients with breast cancer. 17 However, that study was not concerned with molecular subtypes. In addition, we performed survival analysis in ER/ PR-positive or HER2-positive group according to Le X expression. However, the Le X expression was not significantly associated with either RFS or OS in ER/PR-positive or HER2-positive groups (data not shown).
Our results revealed an association between Le X positivity and higher pathologic nodal stage. Shirahama et al 12 reported that increased Le X expression was correlated with an increase in lymph node metastasis in transitional cell carcinoma of the bladder. Elola et al 22 observed that the initial adhesion of human breast cancer cells to endothelium can be mediated by the Le X antigen. These results suggest that Le X expression may be associated with the process of lymph node permeation related to tumor progression. Interestingly, our results showed that Le X expression was associated with a worse prognosis in young patients. Previous studies show that young patients with breast cancer have a poorer prognosis than those who are older at diagnosis. [23] [24] [25] [26] Local recurrence and distant metastases were observed at significantly higher rates in younger patients with TNBC. 27 However, the mechanisms underlying the poor prognosis of younger patients remain to be elucidated. Our results suggest that Le X expression may be associated with tumor progression in young patients with TNBC. Our study included TNBC tumors with the lobular, micropapillary, and mucinous carcinoma subtypes. These tumors are invariably ER-positive. Our TNBC lobular cancer was of the pleomorphic subtype. A recent study reported that TNBC cases comprised 13.2% in the pleomorphic lobular carcinoma group. 28 Furthermore, another recent study with a large sample size revealed that TNBC is a heterogeneous class with variable pathologic subtypes. That study reported that micropapillary and mucinous subtypes also show a triple negativity but with a low frequency. 29 Although Le X is known by many different names, including CD15 and stage-specific embryonic antigen-1 (SSEA-1), in our study, Le X refers to the nonsialylated form of the carbohydrate because sialyl-Le X has different adhesion properties and is found on different tissues and tumors. Previous studies showed that aberrant expression of Le X is one of the oncofetal antigenic changes that occur in early colon cancer development. 30 , 31 Read et al 14 generated a model of medulloblastoma by using the Patched mutant mouse model Ptc+/− and found that Le X was a marker for tumor-propagating cells or tumor stem cells. Le X -positive populations of human glioblastoma multiforme cells are also reportedly enriched in tumor stem cells or tumor-initiating cells. 32 Various studies have investigated the therapeutic potential of targeting the Le X antigen in different ways. In a phase I clinical trial, FC-2.15, which recognizes the Le X antigen, was administered to 5 patients with breast cancer; a remission rate of more than 50% of liver metastases was observed in 2 patient during the trial. 18 ❚Figure 1❚ A, Recurrence-free survival (A; P = .002) and overall survival (B; P =.016) according to Lewis X (Le X ) expression status.
IgG3 antibody, MCS-1, inhibited binding of Le X -positive cells to the vascular endothelium. 22 Further prospective clinical trials are necessary to determine the efficacy of targeted therapies against the Le X antigen and the prognostic effect of Le X . It has been suggested that TNBC is a heterogeneous disease with different prognostic patterns according to specific TNBC subtypes. [33] [34] [35] Previous reports identified several metagenes associated with distinct biological processes in patients with TNBC. Some of the metagenes seem to point to the distinct origins of these cancers (basal-like, 36 apocrine, 37 and claudin low 38 ) and the tumor microenvironment (stroma, 39 blood cell, 40 adipocyte, 36 angiogenesis, 41 and inflammation 42 ).
However, a gene expression signature study of tumorassociated carbohydrate antigens in breast cancer has not been performed to date. Therefore, our findings may provide a basis for new gene expression analyses.
The limitations of this study include the retrospective nature of the study design, relatively short follow-up period, and a relatively small sample size.
In conclusion, our results suggest that Le X expression may provide additional prognostic information for younger patients with TNBC. Le X enables patients with TNBC to be stratified according to pathologic stage. Our findings may also help the design of new gene expression analyses. Further prospective clinical trials are required to investigate the effect of the Le X antigen on clinical outcomes and to confirm the present findings. A B ❚Figure 3❚ Recurrence-free survival (A; P < .001) and overall survival (B; P = .002) according to TNM stage and Lewis X (Le X ) expression.
❚Figure 4❚ Recurrence-free survival (A; P < .001) and overall survival (B; P < .001) according to Lewis X (Le X ) expression in younger patients with triple-negative breast cancer (TNBC). Recurrence-free survival (C; P = .0194) and overall survival (D; P = .661) according to Le X expression in older patients with TNBC. 
